• Jyong Biotech plans a manufacturing facility and U.S. operations center in Texas to support potential commercialization of its investigational drugs.
• The proposed facility would manufacture pharmaceuticals; health supplement production lines are under consideration, subject to planning, regulatory requirements and funding.
• Texas was selected for competitive land costs, favorable taxes and manufacturing incentives.
• The U.S. is its highest-priority market; commercialization depends on regulatory approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150800PRIMZONEFULLFEED9846327) on October 15, 2026, and is solely responsible for the information contained therein.